NewAmsterdam Pharma saw a welcome improvement to its Relative Strength (RS) Rating on Monday, rising from 80 to 83.
IBD's unique rating tracks market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the trailing 52 weeks compares to all the other stocks in our database.
Over 100 years of market history reveals that the top-performing stocks tend to have an RS Rating of over 80 as they begin their biggest climbs.
Hone Your Stock-Picking Skills By Focusing On These Factors
Now is not an ideal time to jump in since it isn't near a proper buy zone, but see if the stock is able to offer and clear an appropriate buy point.
The company showed 0% earnings growth in its most recent report, while sales growth came in at 942%.
NewAmsterdam Pharma holds the No. 69 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, Halozyme Therapeutics and Corcept Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Technical Action?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
